We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 29 juni 2017

Nature Reviews Drug Discovery contents July 2017 Volume 16 Number 7 pp 441-511

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery

 
TABLE OF CONTENTS
 
July 2017 Volume 16 Number 7Advertisement

Nature Reviews Drug Discovery cover
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38
In this issue
Comment
News and Analysis
Research Highlights
Reviews

Also this month
 Featured article:
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green & Guido Kroemer


 

Genomics has met its match!

MAKE MORE MEANINGFUL CONNECTIONS


A powerful first-line phenotyping technology delivering a readout of the molecular phenotype and all its influences, both genetic and non-genetic. See how genomics and metabolomics are breaking through together.


Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 
Advertisement
Nature Outlook: University Spin-offs 

This Outlook presents a portrait of 22 science-based start-up ventures that have emerged from universities around the world to turn laboratory research into practical, profitable products. 

Access the Outlook free online for six months. 
 
Advertisement

BIOPHARMA DEALMAKERS
BioPharma DealmakersCompany Profiles and Partnering Opportunities


 
Advertisement
Focus on Disease models: reproducibility and translation 

Lab Animal, a Nature Research journal focusing on in vivo methods, research and technology with model organisms of human health & disease, presents a special Focus on reproducibility and translation of in vivo research with disease models. 

Access this Focus >

Produced with support from: 
Taconic Biosciences, Inc. 
Charles River
 
Advertisement
MEDTECH DEALMAKERS
A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery

Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications.

Download the issue for FREE
 
 
Comment: Implications of cancer evolution for drug development
Samra Turajlic & Charles Swanton
p441 | doi:10.1038/nrd.2017.78
Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.
Full Text | PDF


 
NEWS AND ANALYSIS

Top
Chinese biopharma starts feeding the global pipeline
Asher Mullard
p443 | doi:10.1038/nrd.2017.94
A handful of discovered-in-China candidates have entered the global clinic, including a few first-in-class contenders.
PDF

NEWS IN BRIEF
Genetic biomarker trumps tissue type in landmark oncology approval
Asher Mullard
p447 | doi:10.1038/nrd.2017.128
PDF

Finding fault with Bial's fatal FAAH inhibitor
Asher Mullard
p447 | doi:10.1038/nrd.2017.129
PDF

Biotech R&D spending continues to rise
Asher Mullard
p447 | doi:10.1038/nrd.2017.130
PDF

BIOBUSINESS BRIEFS
Market watch: Landscape for medical countermeasure development
Christopher Milne, Zachary Peter Smith & Ranjana Chakravarthy
p448 | doi:10.1038/nrd.2017.80
PDF

BIOBUSINESS BRIEFS
Market watch: Upcoming market catalysts in Q3 2017
Sonny Nghiem
p449 | doi:10.1038/nrd.2017.117
PDF

AN AUDIENCE WITH
Yong-Jun Liu
p450 | doi:10.1038/nrd.2017.127
Yong-Jun Liu, head of research at Sanofi, discusses his push to refocus the company on internal early-stage drug discovery.
PDF

FROM THE ANALYST'S COUCH
The ovarian cancer drug market
Jennifer Bamford & Rachel M. Webster
p451 | doi:10.1038/nrd.2017.92
This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.
PDF

RESEARCH HIGHLIGHTS

Top

Cardiovascular disease: BET inhibitor attenuates heart failure
p453 | doi:10.1038/nrd.2017.125
PDF


Endocrinology: Reducing fat and building bone
p454 | doi:10.1038/nrd.2017.121
PDF


Transporters: Natural product provides alternative transport for iron
p454 | doi:10.1038/nrd.2017.124
PDF


Cancer immunotherapy: Macrophages steal the show
p455 | doi:10.1038/nrd.2017.126
PDF


Ageing: Old bone removal
p456 | doi:10.1038/nrd.2017.123
PDF



IN BRIEF

Cancer: Targeting MYC-driven translation | Genetic disorders: Repurposing metformin in FXS | G Protein-Coupled Receptors: Crystal structure of glucagon family receptors
PDF

Drug Discovery
JOBS of the week
Scientists
Immunocore
Sr. Scientific Researcher, NMR Spectroscopy - Structural Biology
Genentech, Inc.
Senior Systems Biologist (m / f)
Sanofi
PK / PD Modellers
GlaxoSmithKline (GSK)
Leader of Antibody And Bi-specific antibody Discovery
Jiangsu Hengrui Medicine
More Science jobs from
Drug Discovery
EVENT
18th International Conference On Alzheimer's Drug Discovery
11.09.17
Jersey City, USA
More science events from
Advertisement
From Bench to Bedside and Back Again

Charles River has proudly partnered with the EBD Group to provide the scientific program for this year's BioPharm America™ Conference. Be a part of this two-day conference that aims to bridge the gap between drug discovery and clinical application.

Register now>>

 
REVIEWS

Top
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
Seth W. Dickey, Gordon Y. C. Cheung & Michael Otto
p457 | doi:10.1038/nrd.2017.23
Efforts to combat bacterial infections by targeting virulence factors are gaining traction, fuelled by the potential to circumvent the development of antibacterial resistance and recent landmark approvals of antivirulence drugs. Here, Otto and colleagues examine the antivirulence drugs in development, highlighting the most promising targets and strategies, as well as caveats to using this approach.
Abstract | Full Text | PDF


Targeting glutamate signalling in depression: progress and prospects
James W. Murrough, Chadi G. Abdallah & Sanjay J. Mathew
p472 | doi:10.1038/nrd.2017.16
Changes in glutamate signalling have been implicated in major depression, and ketamine, which was recently found to act as a rapid-acting antidepressant, affects glutamate signalling in several ways. Murrough and colleagues give an overview of the development of glutamate-signalling modulators for depression and examine studies on the mechanisms of these agents.
Abstract | Full Text | PDF


Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green & Guido Kroemer
p487 | doi:10.1038/nrd.2017.22
Dysregulated autophagy is associated with a variety of conditions, including cancer, neurodegenerative diseases, cardiovascular disorders and infectious diseases. However, despite significant efforts, no specific modulators of autophagy have yet been moved into the clinic. Here, Galluzzi et al. discuss the therapeutic potential of autophagy modulators and consider the key challenges that have limited their development.
Abstract | Full Text | PDF


Advertisement
Leukemia: Collection on Acute Myeloid Leukemia

AML is an area of focus for Leukemia and this collection brings together a number of recent key articles published in the journal. 

Access this collection free online for six months

Funded by a grant from Astex Pharmaceuticals, Inc.
(a member of the Otsuka group)
 
Advertisement
Call for nominations: 2017 John Maddox Prize for Standing up for Science.

Recognising the work of individuals who promote science in the face of hostility. Winners will be announced at a reception in London, as well as in Nature, and will receive £2,000.

Closing date for nominations is 31st July 2017.

Click to learn more
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature